1
2
3
4
5
6
7
8
2
3
4
5
6
7
8
Published In
Archives of Rheumatology
Volume: 36 Issue: 3, September 2021
Pages: 366-374
History
Published Online: September 30, 2021
This work is licensed under a Creative Commons Attribution 4.0 International License.
Veli Yazısız
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Vural Taner Yılmaz
Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey
İsmail Uçar
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Özgür Dandin
Department of General Surgery, Akdeniz University School of Medicine, Antalya, Turkey
Bengisu Aslan
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Funda Erbasan
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Hüseyin Koçak
Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey
Mustafa Ender Terzioğlu
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Veli Yazısız, Vural Taner Yılmaz, İsmail Uçar, Özgür Dandin, Bengisu Aslan, Funda Erbasan, … Mustafa Ender Terzioğlu. (2021). The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients. Archives of Rheumatology, 36(3), 366–374. https://doi.org/10.46497/ArchRheumatol.2021.8500
Abstract
Objectives: The aim of this study was to investigate the efficacy and safety of anti-interleukin-1 (anti-IL-1) agents and tumor necrosis factor‐alpha (TNF-α) inhibitors in renal transplant patients.
Patients and methods: Between February 2014 and February 2020, data of 12 renal transplant recipients (9 males, 3 females; median age: 51 years; range, 19 to 70 years) who received anti-IL-1 agents or TNF-α inhibitors for inflammatory diseases in the post-transplant time period and were followed in a single transplant center (n=12) were retrospectively analyzed. A total of 46 cases were reported in the literature, before the data were collected. The overall outcomes of all cases were analyzed in this study.
Results: Thirty-seven patients received anti-IL-1 agents in the post-transplant period. The main indications for anti-IL-1 agents were familial Mediterranean fever (FMF) and amyloidosis (75.7%). The continuation rate of colchicine treatment in patients with FMF was 85.7%. Anti-IL-1 agents prevented attacks completely in 89.3% of FMF patients. The number of cases used TNF-α inhibitors among renal transplant patients was lower (n=21). The TNF-α inhibitors were used mainly for inflammatory bowel diseases (57.1%) and ankylosing spondylitis (33.3%) and suppressed the disease activity in most of the patients with inflammatory diseases (72.7%). Death (n=3) and malignancies (n=3) were reported in patients who received TNF-α inhibitors, but not in patients who received anti-IL-1. The renal outcomes and graft survival rates were satisfactory in patients who received both anti-IL-1 agents and TNF-α inhibitors.
Conclusion: Our results support that anti-IL-1 agents can be used effectively and safely in renal transplant patients.
Similar Articles
Similar Articles
- Musa DEMİRKAPI, Mustafa Turgut YILDIZGÖREN, Hayal GÜLER, Ayşe Dicle TURHANOĞLU, The Effect of Anti-Tumor Necrosis Factor-Alpha Treatment on Muscle Performance and Endurance in Patients With Ankylosing Spondylitis: A Prospective Follow-Up Study , Archives of Rheumatology: Vol. 32 No. 4 (2017): The Archives of Rheumatology
- Ki-Jo KIM, Chul-Soo CHO, Anemia of Chronic Disease in Ankylosing Spondylitis: Improvement Following Anti-TNF Therapy , Archives of Rheumatology: Vol. 27 No. 2 (2012): The Archives of Rheumatology
- Xinzhu Yuan, Changwei Lin, Yanni Zhang, Hongni He, Lingqin Li, miR-23a-5p Alleviates Gouty Inflammation by Targeting Interleukin-17A and Inhibiting NLR Family Pyrin Domain Containing 3 Inflammasome Activation , Archives of Rheumatology: Vol. 40 No. 4 (2025): Archives of Rheumatology
- Nesrin ŞEN, Mehmet Engin TEZCAN, Anti-tumor necrosis factor treatment in ankylosing spondylitis may not relate to poor prognosis in COVID-19 , Archives of Rheumatology: Vol. 36 No. 1 (2021): The Archives of Rheumatology
- Alper SOYLU, Mehmet Atilla TÜRKMEN, Salih KAVUKÇU, The Rate of Awareness for Familial Mediterranean Fever for Urban Dwellers in Turkey , Archives of Rheumatology: Vol. 27 No. 4 (2012): The Archives of Rheumatology
- Deniz DÜLGEROĞLU ERDOĞDU, Ajda BAL, Özgür KARAAHMET, Sibel ERKOÇ, Tuğba YALÇIN, Aytül ÇAKCI, Efficacy of Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis , Archives of Rheumatology: Vol. 29 No. 4 (2014): The Archives of Rheumatology
- Oznur Kutluk, Nimet Ezgi Dabak, Ayca Ayse Yucel, Ahmet Sukru Alparslan, Fatih Cay, The Association Between Obesity Indices and Non-Alcoholic Fatty Liver Disease in Patients with Ankylosing Spondylitis , Archives of Rheumatology: Vol. 40 No. 4 (2025): Archives of Rheumatology
- Merih BİRLİK, Sedat ÇAPAR, Servet AKAR, İsmail SARI, Fatos ÖNEN, Nurullah AKKOÇ, Comparison of Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Requirement Before and After Tumor Necrosis Factor Inhibitor Treatment in Patients With Rheumatoid Arthritis , Archives of Rheumatology: Vol. 30 No. 3 (2015): The Archives of Rheumatology
- Kenan TURGUTALP, Ahmet KIYKIM, Feray TABAKAN, Anıl TOMBAK, Naci TİFTİK, Onur ÖZHAN3, Secondary Amiloidosis and Familial Mediterranean Fever Mimicking Recurrent Abdominal Sickling Crisis in a Patient with Sickle Cell Anemia , Archives of Rheumatology: Vol. 28 No. 3 (2013): The Archives of Rheumatology
- Özgür ORTANCIL, Nercivan BULMUŞ, Şenay ÖZDOLAP, Sibel KIRAN, Mehmet ARASLI3, Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid Arthritis and Their Relationship with Extra-Articular Manifestations , Archives of Rheumatology: Vol. 26 No. 3 (2011): The Archives of Rheumatology
<< < 1 2 3 4 5 6 7 8 9 10 > >>
You may also start an advanced similarity search for this article.
Article Info
Published In
Journal
Archives of Rheumatology
Volume / Issue
Vol. 36 No. 3 (2021): The Archives of Rheumatology
Pages
366-374
History
Published Online
September 30, 2021
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Affiliations
1
Veli Yazısız
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
2
Vural Taner Yılmaz
Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey
3
İsmail Uçar
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
4
Özgür Dandin
Department of General Surgery, Akdeniz University School of Medicine, Antalya, Turkey
5
Bengisu Aslan
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
6
Funda Erbasan
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
7
Hüseyin Koçak
Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey
8
Mustafa Ender Terzioğlu
Department of Internal Medicine, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey
Cite this Article
Veli Yazısız, Vural Taner Yılmaz, İsmail Uçar, Özgür Dandin, Bengisu Aslan, Funda Erbasan, … Mustafa Ender Terzioğlu. (2021). The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients. Archives of Rheumatology, 36(3), 366–374. https://doi.org/10.46497/ArchRheumatol.2021.8500
Outlines